Conocarpus lancifolius (Combretaceae): Pharmacological Effects, LC-ESI-MS/MS Profiling and In Silico Attributes

In folklore medicine, Conocarpus lancifolius is used to treat various illnesses. The main objective of this study was a comprehensive investigation leaf aqueous extract (CLAE) for its antioxidant, cardioprotective, anxiolytic, antidepressant and memory-enhancing capabilities by using different in vitro, vivo silico models. vitro experimentation revealed that CLAE consumed an ample amount total phenolics (67.70 ± 0.15 µg GAE/mg) flavonoids (47.54 0.45 QE/mg) with stronger antiradical effects through DPPH (IC50 = 16.66 0.42 µg/mL), TAC (77.33 0.41 AAE/mg) TRP (79.11 0.67 assays. also displayed suitable acetylcholinesterase (AChE) inhibitory 110.13 1.71 µg/mL) activity modified Ellman’s method. toxicology examination presented no mortality or any signs clinical toxicity both single-dose repeated-dose tests. line the cardioprotective study, pretreatment found be effective relieving isoproterenol (ISO)-induced myocardial injury rats normalizing heart weight index, serum cardiac biomarkers, lipid profile histopathological variations. noise-stress-induced model behavior attributes, results demonstrated has tendency increase time spent central zone elevated open arms field plus maze tests (examined anxiety assessment), reduced periods immobility forced swimming test (for depression) improved recognition working memory novel object Morris water tests, respectively. Moreover, LC-ESI-MS/MS profiling predicted 53 phytocompounds CLAE. drug-likeness ADMET analysis exhibited majority identified compounds have reasonable physicochemical pharmacokinetic profiles. co-expression molecular docking network indicated top-ranked phytoconstituents act efficiently against key proteins target multiple signaling pathways exert cardiovascular-protectant, activity. Hence, artifact illustrates observed biological properties elucidate significance as sustainable source bioactive phytochemicals, which appears advantageous pursuing further studies development new therapeutic agents desired interest.